GlobeNewswire Inc | Jul 16, 2020 08:00AM EDT

July 16, 2020

LOS ANGELES, July 16, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of CytomX Therapeutics, Inc. investors (NASDAQ: CTMX) (CytomX or the Company) that acquired CytomX securities betweenMay 17, 2018, and May 13, 2020.

Investors are encouraged to contact attorney Lesley F. Portnoy,by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com.

According to the lawsuit, defendants betweenMay 17, 2018, and May 13, 2020 made false and/or misleading statements and/or failed to disclose that: (1) CytomX had downplayed issues with CX-072's efficacy observed in the PROCLAIM-CX-072 clinical program; (2) CytomX had similarly downplayed issues with CX-2009's efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (3) as a result, CytomX's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Please visit our website to review more information and submit your transaction information. If you suffered a loss you have untilJuly 20, 2020to request that the Court appoint you as lead plaintiff.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firms founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.Admitted CA and NY Barlesley@portnoylaw.com310-692-8883www.portnoylaw.com